Atorvastatin/ezetimibe 복합제 복용 후 발생한 시야결손 부작용 사례보고 = Visual Field Defect after Taking Atorvastatin/Ezetimibe, a Case Study

다국어 초록 (Multilingual Abstract)

Atorvastatin is one of the most widely prescribed medications for dyslipidemia treatment. In Korea, post combined therapy with ezetimibe, a 73-year-old woman was reported by a community pharmacy to have experienced visual field defect, which recovered after drug discontinuation. She had never experienced this symptom before, and several studies have reported an association between use of statins and visual disorders such as blurred vision, diplopia, and cataract. Blockage of cholesterol accumulation, oxidative stress, or myopathy is expected to be a cause of this symptom. Naranjo scale, Korean causality assessment algorithm (Ver.2), and World Health Organization-Uppsala Monitoring Center (WHO-UMC) criteria were the three tools used to determine causality between the visual disorder and atorvastatin. The results represent ‘probable’, ‘certain’, and ‘probable/likely’ causality, respectively. Our results, in combination with a review of literature, indicate that ocular adverse effects are highly likely related to atorvastatin

참고문헌 (Reference)

1 Dirks AJ, "Statin-induced apoptosis and skeletal myopathy" 291 (291): C1208-C1212, 2006

2 Mizranita V, "Statin-associated ocular disorders: the FDA and ADRAC data" 37 (37): 844-850, 2015

3 Bahrami B, "Orbital myositis secondary to statin therapy" 203 (203): 365-, 2015

4 Baker SK, "Molecular clues into the pathogenesis of statin-mediated muscle toxicity" 31 (31): 572-580, 2005

5 Willis RA, "Lovastatin decreases coenzyme Q levels in rats" 87 (87): 8928-8930, 1990

6 Zelenka PS, "Lens lipids" 3 (3): 1337-1359, 1984

7 Liantonio A, "Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system" 321 (321): 626-634, 2007

8 Satoh K, "Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischemic rat hearts" 292 (292): 271-275, 1995

9 Satoh K, "Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts" 116 (116): 1894-1898, 1995

10 Ballantyne CM, "Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial" 107 (107): 2409-2415, 2003

11 Lee SH, "Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia" 17 (17): 65-71, 2012

12 "DrugStats Database. Atorvastatin, Drug Usage Statistics, United States, 2006-2016"

13 Fraunfelder FW, "Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor use" 115 (115): 2282-2285, 2008

14 Kawashiri MA, "Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study" 83 (83): 731-739, 2008

15 Littarru GP, "Coenzyme Q10 and statins:biochemical and clinical implications" 7 (7): S168-S174, 2007

16 Kanski JJ, "Clinical Ophthalmology: A Sytematic Approach" Elsevier 269-310, 2011

17 Cenedella RJ, "Cholesterol and cataracts" 40 (40): 320-337, 1996

18 Urso ML, "Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins" 25 (25): 2560-2566, 2005

19 Korean Index of Medical Specialties, "Atorvastatin"

20 Spurgeon D, "Antibiotic use with cholesterol lowering drugs may increase risk of cataracts" 325 (325): 1194-, 2002

21 Machan CM, "Age-related cataract is associated with type 2 diabetes and statin use" 89 (89): 1165-1171, 2012

22 Beltowski J, "Adverse effects of statins-mechanisms and consequences" 4 (4): 209-228, 2009